Mylan Pharmaceuticals gets FDA nod for generic Actos

U.S. Food and Drug Administration approves the first generic version of the pioglitazone hydrochloride tablet

| 1 min read

CANONSBURG, Pa.—The U.S. Food and DrugAdministration (FDA) on Aug. 17 approved the first generic version of Actos tablets, with that first-such-nod going to West Virginia-based Mylan Pharmaceuticals, a subsidiary of Mylan Inc. Pioglitazone is intended to be used along with diet and exercise toimprove blood glucose control in adults with type 2 diabetes.

To continue reading this article, subscribe for FREE to Drug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

About the Author

Jeffrey Bouley
This person does not yet have a bio.

Mylan Pharmaceuticals gets FDA nod for generic Actos

About the Author

Jeffrey Bouley

Related Topics

Subscribe to our eNewsletters

Sponsored

December 2025